Alkem Laboratories Ltd. shares experienced a sharp decline on Friday, falling as much as 5% following the announcement of CEO Vikas Gupta's resignation. According to reports from Moneycontrol, the stock hit an intraday low of ₹5,261, down 4.7% during late afternoon trade. The pharmaceutical company's shares have declined 2.6% year-to-date, reflecting investor concerns about the leadership transition. The company's market capitalisation stands at over ₹63,000 crore, with the stock remaining largely flat over the past one year compared with a 1.5% decline in the Nifty 50.
As reported by Moneycontrol, Gupta will continue in his role until June 30, 2026, ensuring a smooth transition of responsibilities. The company has not yet announced who will succeed Gupta in his leadership position. In his resignation letter, Gupta stated that serving as CEO had been "a profound honour" and highlighted the company's progress in strengthening its market position and advancing its R&D pipeline. He emphasized that he would support the management during the transition period, noting his pride in what the team achieved together in navigating the evolving global pharmaceutical landscape.
According to the exchange filing reported by Moneycontrol, Gupta has committed to assisting the management team to ensure a seamless handover of all ongoing strategic initiatives and leadership responsibilities until his departure date. He emphasized his readiness to support the transition process during this transitional period, demonstrating his dedication to ensuring a smooth leadership transition for the pharmaceutical company.
